STAT3 Inhibition in a Murine Model of Human Breast Cancer-Induced Bone Pain Delays Onset of Nociception

Introduction/Aim: Alterations in extracellular glutamate levels have been previously found to contribute to cancer-induced bone pain (CIBP). Increased activity of system xc-, a cystine-glutamate membrane antiporter, has been previously implicated in our lab in these nociceptive behaviours. System xc...

Full description

Bibliographic Details
Main Authors: Manu Sharma, Katja Linher-Melville, Jesse Sidhu, Peter Nakhla, Gurmit Singh
Format: Article
Language:English
Published: Taylor & Francis Group 2019-07-01
Series:Canadian Journal of Pain
Subjects:
Online Access:http://dx.doi.org/10.1080/24740527.2019.1641060
_version_ 1818929089509064704
author Manu Sharma
Katja Linher-Melville
Jesse Sidhu
Peter Nakhla
Gurmit Singh
author_facet Manu Sharma
Katja Linher-Melville
Jesse Sidhu
Peter Nakhla
Gurmit Singh
author_sort Manu Sharma
collection DOAJ
description Introduction/Aim: Alterations in extracellular glutamate levels have been previously found to contribute to cancer-induced bone pain (CIBP). Increased activity of system xc-, a cystine-glutamate membrane antiporter, has been previously implicated in our lab in these nociceptive behaviours. System xc- subunit xCT, is further positively regulated by signal transducer and activator of transcription 3 (STAT3). In the current investigation, we hypothesized that DR-1–55-mediated inhibition of pSTAT3 will lead to decreased nociceptive behaviours in a validated xCT overexpression model of CIBP. Methods: Using a murine xenograft CIBP model, a high glutamate-releasing xCT/pSTAT3 overexpressing human breast cancer cell line (T47D clone) was injected into the distal epiphysis of the femur of female nude mice. Nociceptive behaviours were monitored through automated von Frey, dynamic weight bearing, and open field testing for the study duration. Three weeks after cell inoculation, a 14-day schedule of intraperitoneal injections of DR-1–55 or vehicle were administered. Results: In vitro, there were elevated levels of glutamate, IL-6, and IL- 1β exhibited in the T47D clone. These cells also showed significant nociceptive behaviours earlier than the T47D wild type (WT). Treatment with DR-1–55 significantly delayed the onset and severity of spontaneous and induced nociceptive behaviours, as seen with behavioural testing. Discussion/Conclusions: This study shows that targeting pSTAT3 may be a viable treatment when managing CIBP, and can be a molecule of interest in future studies.
first_indexed 2024-12-20T03:39:16Z
format Article
id doaj.art-7b4b5b5e6607490cbc4e2e74416d5bea
institution Directory Open Access Journal
issn 2474-0527
language English
last_indexed 2024-12-20T03:39:16Z
publishDate 2019-07-01
publisher Taylor & Francis Group
record_format Article
series Canadian Journal of Pain
spelling doaj.art-7b4b5b5e6607490cbc4e2e74416d5bea2022-12-21T19:54:48ZengTaylor & Francis GroupCanadian Journal of Pain2474-05272019-07-0132696910.1080/24740527.2019.16410601641060STAT3 Inhibition in a Murine Model of Human Breast Cancer-Induced Bone Pain Delays Onset of NociceptionManu Sharma0Katja Linher-Melville1Jesse Sidhu2Peter Nakhla3Gurmit Singh4McMaster UniversityMcMaster UniversityMcMaster UniversityMcMaster UniversityMcMaster UniversityIntroduction/Aim: Alterations in extracellular glutamate levels have been previously found to contribute to cancer-induced bone pain (CIBP). Increased activity of system xc-, a cystine-glutamate membrane antiporter, has been previously implicated in our lab in these nociceptive behaviours. System xc- subunit xCT, is further positively regulated by signal transducer and activator of transcription 3 (STAT3). In the current investigation, we hypothesized that DR-1–55-mediated inhibition of pSTAT3 will lead to decreased nociceptive behaviours in a validated xCT overexpression model of CIBP. Methods: Using a murine xenograft CIBP model, a high glutamate-releasing xCT/pSTAT3 overexpressing human breast cancer cell line (T47D clone) was injected into the distal epiphysis of the femur of female nude mice. Nociceptive behaviours were monitored through automated von Frey, dynamic weight bearing, and open field testing for the study duration. Three weeks after cell inoculation, a 14-day schedule of intraperitoneal injections of DR-1–55 or vehicle were administered. Results: In vitro, there were elevated levels of glutamate, IL-6, and IL- 1β exhibited in the T47D clone. These cells also showed significant nociceptive behaviours earlier than the T47D wild type (WT). Treatment with DR-1–55 significantly delayed the onset and severity of spontaneous and induced nociceptive behaviours, as seen with behavioural testing. Discussion/Conclusions: This study shows that targeting pSTAT3 may be a viable treatment when managing CIBP, and can be a molecule of interest in future studies.http://dx.doi.org/10.1080/24740527.2019.1641060STAT3cancer-induced bone painnociceptiveallodyniabreast cancercancercancer pain
spellingShingle Manu Sharma
Katja Linher-Melville
Jesse Sidhu
Peter Nakhla
Gurmit Singh
STAT3 Inhibition in a Murine Model of Human Breast Cancer-Induced Bone Pain Delays Onset of Nociception
Canadian Journal of Pain
STAT3
cancer-induced bone pain
nociceptive
allodynia
breast cancer
cancer
cancer pain
title STAT3 Inhibition in a Murine Model of Human Breast Cancer-Induced Bone Pain Delays Onset of Nociception
title_full STAT3 Inhibition in a Murine Model of Human Breast Cancer-Induced Bone Pain Delays Onset of Nociception
title_fullStr STAT3 Inhibition in a Murine Model of Human Breast Cancer-Induced Bone Pain Delays Onset of Nociception
title_full_unstemmed STAT3 Inhibition in a Murine Model of Human Breast Cancer-Induced Bone Pain Delays Onset of Nociception
title_short STAT3 Inhibition in a Murine Model of Human Breast Cancer-Induced Bone Pain Delays Onset of Nociception
title_sort stat3 inhibition in a murine model of human breast cancer induced bone pain delays onset of nociception
topic STAT3
cancer-induced bone pain
nociceptive
allodynia
breast cancer
cancer
cancer pain
url http://dx.doi.org/10.1080/24740527.2019.1641060
work_keys_str_mv AT manusharma stat3inhibitioninamurinemodelofhumanbreastcancerinducedbonepaindelaysonsetofnociception
AT katjalinhermelville stat3inhibitioninamurinemodelofhumanbreastcancerinducedbonepaindelaysonsetofnociception
AT jessesidhu stat3inhibitioninamurinemodelofhumanbreastcancerinducedbonepaindelaysonsetofnociception
AT peternakhla stat3inhibitioninamurinemodelofhumanbreastcancerinducedbonepaindelaysonsetofnociception
AT gurmitsingh stat3inhibitioninamurinemodelofhumanbreastcancerinducedbonepaindelaysonsetofnociception